Swiss National Bank
JANX icon

Swiss National Bank’s Janux Therapeutics JANX Stock Holding History

Swiss National Bank’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.07M Hold
77,100
– – ﹤0.01% 2130
2025
Q4 		$1.06M Buy
77,100
+2,500
+3% +$58.8K ﹤0.01% 2154
2025
Q3 		$1.82M Sell
74,600
-4,500
-6% -$110K ﹤0.01% 1904
2025
Q2 		$1.83M Hold
79,100
– – ﹤0.01% 1853
2025
Q1 		$2.14M Hold
79,100
– – ﹤0.01% 1720
2024
Q4 		$4.24M Buy
79,100
+38,400
+94% +$2.03M ﹤0.01% 1436
2024
Q3 		$1.85M Hold
40,700
– – ﹤0.01% 1913
2024
Q2 		$1.7M Buy
40,700
+8,900
+28% +$418K ﹤0.01% 1894
2024
Q1 		$1.2M Hold
31,800
– – ﹤0.01% 2128
2023
Q4 		$341K Buy
31,800
+9,000
+39% +$77.8K ﹤0.01% 2515
2023
Q3 		$230K Hold
22,800
– – ﹤0.01% 2599
2023
Q2 		$271K Sell
22,800
-4,200
-16% -$56.1K ﹤0.01% 2596
2023
Q1 		$327K Buy
+27,000
New +$449K ﹤0.01% 2596

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Swiss National Bank's JANX Position: Q1 2026 in Review

Swiss National Bank held its Janux Therapeutics (JANX) position steady in Q1 2026 at 77,100 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2130.

Swiss National Bank first reported a position in JANX in Q1 2023 and has held it in 13 quarters since. The position peaked at $4.24M in Q4 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • Swiss National Bank held 77,100 shares of Janux Therapeutics worth $1.07M as of Q1 2026.
  • Swiss National Bank left its Janux Therapeutics share count unchanged in Q1 2026.
  • Janux Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q1 2026, its #2130 holding.
  • Swiss National Bank first reported a position in Janux Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Swiss National Bank's Janux Therapeutics position peaked at $4.24M in Q4 2024.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.